AdaptHealth Earnings Call: Growth Wins Over Margin Pain

Adapthealth ((AHCO)) has held its Q1 earnings call. Read on for the main highlights of the call.

AdaptHealth’s latest earnings call struck a cautiously upbeat tone, as management emphasized strategic wins and long‑term positioning despite near‑term profit and cash flow pressure. Executives highlighted record organic growth, successful execution on a massive new capitated contract, and improved financing terms, arguing these offsets temporary margin compression and negative free cash flow.

Massive Capitated Transition Reshapes Growth Profile

AdaptHealth completed what it called the largest patient transition in home medical equipment history, securing exclusive status for more than 10 million new members. The move lifted capitated membership roughly sevenfold to about 15 million, with capitated net revenue contributing 9.2% of consolidated revenue in the first quarter.

Revenue Beats Guidance With Strong Organic Growth

First quarter net revenue reached $819.8 million, up 5.4% year over year and about $22 million ahead of the midpoint of guidance. Organic growth was a robust 9.1%, with roughly 500 basis points tied to the new capitated contract and about 400 basis points from the company’s base business.

Sleep and Respiratory Segments Deliver Outperformance

Sleep Health remained a standout, with net revenue rising 13.3% to $358.5 million and PAP new starts hitting a record level, underscoring strong demand. Respiratory Health also posted healthy results, with revenue up 7.6% to $178.1 million and oxygen new starts climbing 12.8% year over year.

Wellness at Home Rebounds Organically After Portfolio Pruning

Wellness at Home reported a 10.3% revenue decline to $141.0 million, reflecting the sale of $35.8 million of noncore assets that distorted headline growth. Adjusted for these dispositions, the segment actually generated 11% organic growth, suggesting underlying recovery after strategic portfolio cleanup.

Digital and AI Investments Start to Scale

Technology was a key theme, with AI‑enabled tools moving beyond pilot into live operations across scheduling, contact centers, and resupply. About a quarter of scheduling is now touchless versus manual a year ago, while the MyApp portal surpassed 412,000 users and faster order conversion is improving service and efficiency.

Refinancing Boosts Liquidity and Lowers Interest Costs

Management highlighted a $1.1 billion refinancing completed in April, including a Term Loan A, a delayed‑draw term facility, and a $450 million revolver maturing in 2031. The new structure extends maturities, lowers the weighted average cost of debt, and reflects recent credit rating upgrades, giving AdaptHealth more financial flexibility.

Guidance Raised on Revenue While Profit Targets Hold

The company nudged full‑year net revenue guidance higher by $10 million to a range of $3.45 billion to $3.52 billion on the back of strong Q1 and capitated ramp. Despite near‑term cost pressure, management kept its full‑year adjusted EBITDA target of $680 million to $730 million and free cash flow outlook of $175 million to $225 million intact.

Cash Flow Stable Operationally, Stronger Back Half Expected

Operating cash flow in Q1 was $93.7 million, essentially flat versus last year, but heavy investment flipped free cash flow to a $27.5 million loss. Management reiterated that CapEx should normalize later this year and projected roughly $100 million of free cash flow in both the third and fourth quarters as the contract matures.

Labor Cost Spike Weighs on Quarterly Profit

Short‑term labor inflation tied to the capitated rollout hit profitability, adding about $12 million of expense in the quarter. Roughly $8 million came from variable labor to accelerate member onboarding and $4 million from elevated wages and benefits, with management expecting these costs to normalize by the end of the second quarter.

EBITDA and Margins Lag Targets in Transition Phase

Adjusted EBITDA came in at $121.2 million, translating to a 14.8% margin and roughly $7 million below internal expectations. Executives attributed the shortfall primarily to transition‑related labor and benefits, stressing that capitated contracts should ultimately support higher structural margins once fully ramped.

CapEx Surge and Negative Free Cash Flow Seen as Temporary

Free cash flow turned negative in Q1 as capital expenditures jumped to $121.2 million, largely to support equipment needs for the new capitated members. Management guided to another quarter of elevated CapEx and only modest positive free cash flow in Q2 before returning to a more normal capital and cash profile in the second half.

Leverage Ticks Higher but Deleveraging Remains a Priority

Net debt stood at about $1.84 billion and net leverage rose to roughly 3.0x, up from 2.75x, partly due to a $100 million revolver draw used to acquire assets. The company reiterated its goal of paying down the revolver and driving net leverage back toward 2.5x, using stronger back‑half cash generation.

Execution Friction from Rapid Multi‑Party Rollout

The aggressive acceleration of a multi‑phase, three‑party go‑live created operational inefficiencies and duplicated onboarding efforts across regions. These complexities required more temporary labor and made near‑term EBITDA harder to forecast, though management framed them as one‑time growing pains of a strategic contract.

Reported Wellness at Home Decline Masks Core Strength

Headline numbers showed a 10.3% revenue drop in Wellness at Home to $141.0 million, driven by exits from noncore and custom rehab assets. Management argued that investors should focus on the 11% organic growth metric, which better reflects the performance of the remaining, more focused franchise.

Margins Under Pressure Until Capitated Contracts Mature

Initial ramp‑up of capitated contracts introduced new fixed costs and extra variable labor, compressing margins in the first quarter. While this pushed adjusted EBITDA margin below long‑term targets, the company expects margin expansion as volume scales and transition expenses roll off.

Forward Guidance Signals Confidence in Second‑Half Upside

For the second quarter, AdaptHealth projected revenue of $840 million to $860 million and an adjusted EBITDA margin near 19%, implying just over $160 million of EBITDA and modest positive free cash flow despite elevated CapEx. Management reiterated expectations for free cash flow normalization and roughly $100 million in each of the third and fourth quarters as labor and CapEx pressures ease.

AdaptHealth’s earnings call painted a picture of a business trading short‑term margin strain for long‑term growth and scale benefits. Investors will need to watch execution on the capitated rollout, normalization of labor and CapEx, and progress toward deleveraging, but management’s reaffirmed profit and cash targets suggest underlying confidence in the trajectory.